Stock listing

TASE:BLRX BioLineRX Ltd. מניה‎

Home listing (TASE) of BioLineRX Ltd.

Follow BioLineRX Ltd. into a list and get an email when it puts out news.

Share price · TASE:BLRX

1.00 ILA (agorot) 0.00 (0.0%)

Close on Nov 19, 2026

Past year -41.2% · daily closes, Nov 19, 2025 – Nov 19, 2026, adjusted for splits
Day range
1.00 – 1.00 ILA (agorot)Nov 19, 2026
Volume
700,000 sharesNov 19, 2026
Market cap
29.87M ILSAt the close on Nov 19, 2026 · price × 2.99B shares outstanding
52-week range
1.00 – 2.00 ILA (agorot)Lowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
42,259 ILSMedian day 2.34M shares · 2 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026
BioLineRX Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TASE:BLRX · Home1.00 ILA (agorot)0.00 (0.0%)700,0001.001.001.001.00Close on Nov 19, 2026
NASDAQ:BLRX$0.964 USD-0.096 (-9.1%)38,775$1.096$1.096$0.780$1.060Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 19, 2026 – Nov 19, 2026 · TASE:BLRX · ILA (agorot), adjusted for splits

DayCloseChange%OpenHighLowVolume
1.000.000.0%1.001.001.00700,000
1.000.000.0%1.001.001.00900,000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.00600,000
1.000.000.0%1.001.001.00200,000
1.000.000.0%1.001.001.00400,000
1.000.000.0%1.001.001.00700,000
1.000.000.0%1.001.001.00200,000
1.000.000.0%1.001.001.0050,000
1.000.000.0%1.001.001.000
1.00-0.10-9.1%1.001.101.001,625,200
1.10+0.10+10.0%1.001.101.006,753,917
1.000.000.0%1.001.101.001,383,000
1.00-0.10-9.1%1.001.101.004,785,451
1.100.000.0%1.101.101.00782,873
1.100.000.0%1.101.101.10100,000
1.10+0.10+10.0%1.001.101.001,348,066
1.00-0.20-16.7%1.101.201.0011,020,588
1.20+0.10+9.1%1.101.201.101,457,394
1.10-0.10-8.3%1.201.201.10593,428
1.20+0.10+9.1%1.101.201.10103,454
1.100.000.0%1.101.201.103,630,646
1.10-0.10-8.3%1.201.201.009,649,668
1.20+0.10+9.1%1.201.201.202,431,817
1.10-0.10-8.3%1.101.201.107,257,431
1.200.000.0%1.201.301.106,635,983
1.200.000.0%1.201.301.205,015,601
1.200.000.0%1.201.301.209,981,993
1.200.000.0%1.201.301.202,645,741
1.200.000.0%1.201.301.204,154,400
1.200.000.0%1.201.301.20911,840
1.200.000.0%1.301.301.203,583,282
1.20-0.10-7.7%1.301.301.202,863,589
1.30-0.10-7.1%1.301.401.208,709,923
1.400.000.0%1.301.401.30714,283
1.40+0.10+7.7%1.301.401.30373,403
1.300.000.0%1.301.401.301,425,362
1.30+0.10+8.3%1.401.401.301,285,100
1.20-0.10-7.7%1.301.401.203,185,320
1.300.000.0%1.301.401.301,297,651
1.300.000.0%1.301.401.303,025,847
1.300.000.0%1.401.401.303,441,553
1.300.000.0%1.301.401.3014,754,104
1.300.000.0%1.401.401.304,248,734
1.300.000.0%1.301.401.305,113,703
1.30-0.20-13.3%1.401.401.303,957,678
1.500.000.0%1.501.501.305,034,182
1.50+0.10+7.1%1.401.501.4057,112
1.40+0.10+7.7%1.401.501.40395,656
1.30-0.10-7.1%1.401.501.302,343,878
1.400.000.0%1.401.501.303,995,603
1.40-0.10-6.7%1.401.501.405,971,703
1.50+0.10+7.1%1.401.501.4020,148,276
1.40-0.10-6.7%1.501.501.40539,856
1.50+0.10+7.1%1.501.501.50375,762
1.40-0.10-6.7%1.501.601.402,669,881
1.500.000.0%1.601.601.403,611,319
1.50-0.10-6.3%1.601.601.504,398,958
1.60+0.10+6.7%1.601.601.60526,968
1.500.000.0%1.501.601.501,389,466
1.50+0.10+7.1%1.501.601.508,099,666

Splits

1 split · TASE:BLRX · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
Ticker
TASE:BLRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
TASE
Currency
ILA

What changed lately

Latest news

All BioLineRX Ltd. news

BioLineRX Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
9 in the last 12 months · 19 in all · newest Sep 10, 2026 · oldest 2025
Calls
25 calls with a replay · 25 with a transcript · latest Aug 31, 2026
Decks
37 decks · latest July 2026

Where BioLineRX Ltd. is listed

ListingExchangeCountryCurrency
TASE:BLRX · Home listing · This pageTASEIsraelILA
NASDAQ:BLRXNASDAQUnited StatesUSD
BOATS:BLRXBOATSUnited StatesUSD
Frankfurt:YP2FrankfurtGermanyEUR
gettex:YP2gettexGermanyEUR
Lang & Schwarz:A41038Lang & SchwarzGermanyEUR
Munich:YP2MunichGermanyEUR
Stuttgart:YP2StuttgartGermanyEUR

Valuation

EV/sales 8.6× against a median of 8.5×: 3rd lowest of 5 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · price Nov 19, 2026

Enterprise value
33.99M ILS
P/E
Loss
EV/sales
8.6×
EV/EBITDA
Negative EBITDA
Price/book
0.5×
Gross margin
80.5%
Operating margin
−871.8%
Net margin
−171.7%
Debt to equity
0.3×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BioLineRX Ltd. · TASE:BLRXUS$8.90MUS$10.13Mn/a8.6×n/a0.5×−171.7%0.3×n/a
Genvor Incorporated · OTC:GNVRUS$9.47MUS$9.27Mn/an/an/an/an/an/a0.44
Poxel SA · EURONEXT:POXELUS$9.27MUS$73.95Mn/an/an/an/an/an/an/a
TScan Therapeutics, Inc. · NASDAQ:TCRXUS$9.27M−US$30.80Mn/a−5.9×n/a0.2×n/a0.9×1.66
Rapid Dose Therapeutics Corp · CSE:DOSEUS$9.13MUS$9.12Mn/a5.1×n/an/a−123.1%n/a0.64
CytoMed Therapeutics Limited · NASDAQ:GDTCUS$9.01MUS$8.23Mn/a14.7×n/a2.3×−730.3%0.1×0.16
PreveCeutical Medical Inc · CSE:PREVUS$8.97MUS$8.95Mn/an/an/an/an/an/a0.73
CalciMedica, Inc. · NASDAQ:CALCUS$8.69MUS$1.82Mn/an/an/a2.1×n/a1.6×0.54
Active Biotech AB · OMXSTO:ACTIUS$8.67MUS$4.38Mn/an/an/a2.4×n/a0.0×n/a
BioVie Inc. · NASDAQ:BIVIUS$8.58MUS$1.10Mn/an/an/a1.3×n/a0.0×1.84
Vyome Holdings, Inc. · NASDAQ:HINDUS$8.42MUS$1.82Mn/a11.9×n/a1.3×n/a0.1×1.34
Median of the othersUS$8.99MUS$6.31M8.5×1.7×−426.7%0.1×0.69

Forecasts

Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
954.07 ILA · Analysts' mean
EPS, year to Dec 2026
0.00 · 1 analyst
Revenue, year to Dec 2026
1.62M · 2 analysts

Team and board

Officers

OfficerRole
Philip A. SerlinCHIEF EXECUTIVE OFFICER
Mali ZeeviCHIEF FINANCIAL OFFICER
Bela NeimanVICE PRESIDENT, ANALYTICAL CHEMISTRY
Efrat HalbfingerVICE PRESIDENT, CHEMISTRY AND FORMULATION
Irit Gliko-KabirVICE PRESIDENT, CLINICAL OPERATIONS
Jael BirenbergVICE PRESIDENT, REGULATORY AFFAIRS, QUALITY ASSURANCE & PHARMACOVIGILANCE
Ella SoraniCHIEF DEVELOPMENT OFFICER

Board

DirectorRole
Aharon SchwartzCHAIRMAN
Avraham MolchoBOARD MEMBER
BJ BormannBOARD MEMBER
Gal CohenBOARD MEMBER
Rafael HofsteinBOARD MEMBER
Rami DarBOARD MEMBER
Sandra PanemBOARD MEMBER
Shaoyu YanBOARD MEMBER

Events

Next results
Nov 23, 2026

Calls

CallWhenStatus
BioLineRX (TASE:BLRX) Q3 2026 Earnings CallMon, Nov 23, 2026 · 8:30 AM ETUpcoming
BioLineRX (TASE:BLRX) Q2 2026 Earnings CallMon, Aug 31, 2026 · 8:30 AM ETReplay
BioLineRX (TASE:BLRX) Q1 2026 Earnings CallWed, May 27, 2026 · 8:30 AM ETReplay
BioLineRX (TASE:BLRX) Q4 2025 Earnings CallMon, Mar 23, 2026 · 8:30 AM ETReplay
BioLineRX (TASE:BLRX) Q3 2025 Earnings CallMon, Nov 24, 2025 · 8:30 AM ETReplay
BioLineRX (TASE:BLRX) Q2 2025 Earnings CallThu, Aug 14, 2025 · 8:30 AM ETReplay
BioLineRX (TASE:BLRX) Q1 2025 Earnings CallTue, May 27, 2025 · 8:30 AM ETReplay
BioLineRX (TASE:BLRX) Q4 2024 Earnings CallMon, Mar 31, 2025 · 8:30 AM ETReplay
BioLineRX (TASE:BLRX) Q3 2024 Earnings CallMon, Nov 25, 2024 · 8:30 AM ETReplay
BioLineRX (TASE:BLRX) Q2 2024 Earnings CallThu, Aug 15, 2024 · 8:30 AM ETReplay
All 26 calls
CallWhenStatus
BioLineRX (TASE:BLRX) Q1 2024 Earnings CallTue, May 28, 2024 · 8:30 AM ETReplay
BioLineRX (TASE:BLRX) Q4 2023 Earnings CallTue, Mar 26, 2024 · 8:30 AM ETReplay
BioLineRX (TASE:BLRX) Q3 2023 Earnings CallMon, Nov 20, 2023 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q1 2023 Earnings CallWed, May 24, 2023 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q4 2022 Earnings CallWed, Mar 22, 2023 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q3 2022 Earnings CallTue, Nov 15, 2022 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q2 2022 Earnings CallTue, Aug 16, 2022 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q1 2022 Earnings CallWed, May 11, 2022 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q4 2021 Earnings CallWed, Mar 16, 2022 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q3 2021 Earnings CallThu, Nov 18, 2021 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q2 2021 Earnings CallWed, Aug 18, 2021 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q1 2021 Earnings CallWed, May 26, 2021 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q4 2020 Earnings CallTue, Feb 23, 2021 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q3 2020 Earnings CallMon, Nov 23, 2020 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q2 2020 Earnings CallThu, Aug 06, 2020 · 10:00 AM ETReplay
BioLineRX (TASE:BLRX) Q1 2020 Earnings CallWed, May 20, 2020 · 10:00 AM ETReplay

Results days

QuarterResultsShare move
Quarter to Jun 30, 2026Aug 31, 2026 · Before open+7.1%
Quarter to Dec 31, 2025Mar 23, 2026 · Before open−7.1%
Quarter to Sep 30, 2025Nov 24, 2025 · Before open+5.6%
Q2 2025Aug 14, 2025 · Before open0.0%
Quarter to Dec 31, 2024Mar 31, 2025 · Before open0.0%
Quarter to Sep 30, 2024Nov 25, 2024 · Before open−9.3%
Quarter to Dec 31, 2023Mar 26, 2024 · Before open−11.4%
Quarter to Sep 30, 2023Nov 20, 2023 · Before open−0.3%
Q2 2023Aug 30, 2023 · Before open+2.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck39 slidesJuly 2026
Q1 2026 Earnings PresentationEarnings28 slidesMay 27, 2026
Technical Presentation (December 2020)Technical14 slidesDec 16, 2020
Technical Presentation (December 2020)Technical49 slidesDec 16, 2020
Investor Presentation (February 2019)Investor deck31 slidesFeb 4, 2019
Investor Presentation (October 2018)Investor deck30 slidesOct 1, 2018
Investor Presentation (June 2018)Investor deck32 slidesJune 2018
Investor Presentation (April 2018)Investor deck31 slidesApril 2018
Investor Presentation (March 2018)Investor deck32 slidesMarch 2018
Investor Presentation (December 2017)Investor deck41 slidesDec 5, 2017
All 37 decks
DeckKindSlidesDate
Investor Presentation (September 2017)Investor deck34 slidesSeptember 2017
Investor Presentation (June 2017)Investor deck39 slidesJun 12, 2017
Investor Presentation (January 2017)Investor deck22 slidesJan 9, 2017
Investor Presentation (July 2016)Investor deck35 slidesJuly 2016
Investor Presentation (May 2016)Investor deck32 slidesMay 2016
Investor Presentation (March 2016)Investor deck35 slidesMarch 2016
Investor Presentation (March 2015)Investor deck38 slidesMar 5, 2015
Investor Presentation (February 2015)Investor deck37 slidesFebruary 2015
Investor Breakfast at TASE (December 2014)Conference44 slidesDec 24, 2014
Investor Day (December 2014)Investor day33 slidesDec 12, 2014
Q3 2014 Earnings PresentationEarnings15 slidesNov 10, 2014
Investor Presentation (September 2014)Investor deck37 slidesSeptember 2014
Q2 2014 Earnings PresentationEarnings14 slidesAug 6, 2014
Q1 2014 Earnings PresentationEarnings16 slidesMay 20, 2014
FY2013 Earnings PresentationEarnings19 slidesMar 17, 2014
Investor Presentation (March 2014)Investor deck50 slidesMar 3, 2014
Investor Presentation (March 2014)Investor deck38 slidesMarch 2014
Investor Presentation (January 2014)Investor deck41 slidesJanuary 2014
Q3 2013 Earnings PresentationEarnings17 slidesNov 13, 2013
Investor Presentation (June 2013)Investor deck51 slidesJune 2013
Investor Presentation (April 2013)Investor deck53 slidesApr 30, 2013
Corporate Update (March 2013)Corporate update12 slidesMar 20, 2013
Investor Presentation (January 2013)Investor deck37 slidesJanuary 2013
Investor Presentation (December 2012)Investor deck31 slidesDecember 2012
Investor Presentation (September 2011)Investor deck53 slidesSeptember 2011
Investor Presentation (July 2010)Investor deck39 slidesJuly 2010
Investor Presentation (April 2010)Investor deck45 slidesApril 2010

Open Decks

IPO

Withdrawn on Jul 1, 2011. Filed with the SEC to go public on Sep 24, 2010.

Underwriters
JMP Securities, Oppenheimer & Co. · In the order on the cover

Steps

StepWhen
Filed publiclySep 24, 2010
Filing withdrawnJul 1, 2011

Open IPO · From the cover of the prospectus (F-1) filed Sep 24, 2010

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.18M28.9M4.80M00
Cost of revenue230.0K9.26M3.69M00
Gross profit950.0K19.7M1.11M00
Research and development8.09M9.15M12.5M17.6M19.5M18.2M23.4M19.8M19.5M11.2M
Selling, general and administrative3.14M6.32M6.31M5.07M4.31M3.91M3.82M4.43M4.04M3.98M
Operating income-10.3M-20.4M-49.7M-29.2M-24.8M-22.9M-28.1M-25.6M-25.2M-16.5M
Depreciation and amortization523.0K4.07M1.38M654.0K703.0K934.0K940.0K545.0K481.0K482.0K
EBITDA-9.76M-16.3M-48.3M-28.5M-24.1M-22.0M-27.2M-25.1M-24.8M-16.0M
Interest expense1.25M9.07M2.14M1.79M984.0K1.47M2.28M473.0K21.0K22.0K
Income tax0000000
Net income-2.03M-9.22M-60.6M-25.0M-27.1M-30.0M-25.4M-23.0M-24.4M-15.8M
Earnings per share, basic0.00-0.01-0.06-0.03-0.04-0.12
Earnings per share, diluted0.00-0.01-0.06-0.03-0.04-0.12

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.25M10.4M4.25M10.6M13.0M16.8M5.30M3.40M5.11M2.47M
Inventory2.15M3.15M1.95M0
Current assets23.7M27.1M47.2M52.0M57.4M22.9M28.2M32.0M50.4M36.1M
Property, plant and equipment160.0K386.0K473.0K726.0K952.0K1.34M1.82M2.23M2.50M2.60M
Total assets40.9M38.9M63.9M76.4M81.4M47.3M53.6M56.2M61.0M38.9M
Accounts payable3.49M5.58M10.9M6.97M5.57M5.92M7.79M4.49M5.52M2.59M
Current liabilities12.1M15.4M42.8M10.7M9.72M10.6M12.0M6.75M6.72M3.66M
Total debt4.48M4.48M3.15M1.54M2.76M5.83M8.49M8.73M250.0K343.0K
Total liabilities17.6M25.4M50.7M25.5M13.3M25.3M20.2M14.9M8.08M3.91M
Shareholders' equity18.2M13.5M13.2M50.8M68.1M22.0M33.4M41.3M52.9M35.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-8.07M-43.9M-22.6M-26.2M-23.6M-23.2M-22.7M-24.2M-20.5M-14.5M
Capital spending-25.0K-53.0K-116.0K-131.0K-97.0K0-67.0K-173.0K-338.0K-52.0K
Free cash flow-8.10M-43.9M-22.7M-26.4M-23.7M-23.2M-22.7M-24.4M-20.9M-14.6M
Cash from investing-8.54M29.4M1.44M4.01M-38.2M16.7M5.26M9.55M-15.9M9.30M
Cash from financing8.88M20.7M15.1M20.4M57.7M17.9M19.2M13.1M38.7M2.09M
Change in cash-7.74M6.16M-6.11M-1.80M-4.05M11.3M1.78M-1.54M2.21M-3.13M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 18, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerNov 16, 2026Current reportSEC
6-K · Report of a foreign issuerOct 23, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveOct 5, 2026Other filingsSEC
424B3 · ProspectusOct 2, 2026Offer documentSEC
F-1 · Registration statementSep 25, 2026Offer documentSEC
6-K · Report of a foreign issuerSep 24, 2026Current reportSEC
6-K · Report of a foreign issuerSep 10, 2026Current reportSEC
DSep 9, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
424B5 · ProspectusAug 31, 2026Offer documentSEC
6-K · Report of a foreign issuerAug 31, 2026Current reportSEC
6-K · Report of a foreign issuerAug 31, 2026Current reportSEC
6-K · Report of a foreign issuerAug 28, 2026Current reportSEC
6-K · Report of a foreign issuerAug 18, 2026Current reportSEC
6-K · Report of a foreign issuerJul 8, 2026Current reportSEC
6-K · Report of a foreign issuerMay 27, 2026Current reportSEC
6-K · Report of a foreign issuerMay 22, 2026Current reportSEC
6-K · Report of a foreign issuerMay 19, 2026Current reportSEC
6-K · Report of a foreign issuerApr 28, 2026Current reportSEC
3 · Initial statement of ownershipApr 10, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 30, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 30, 2026Insider tradeSEC
20-F/A · Annual report, amendedMar 27, 2026Annual reportSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 26, 2026Current reportSEC
6-K · Report of a foreign issuerMar 23, 2026Current reportSEC
20-F · Annual reportMar 23, 2026Annual reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerFeb 23, 2026Current reportSEC
S-8 · Registration statement for employee plansJan 23, 2026Offer documentSEC
6-K · Report of a foreign issuerNov 24, 2025Current reportSEC
6-K · Report of a foreign issuerNov 17, 2025Current reportSEC
6-K · Report of a foreign issuerSep 29, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerAug 14, 2025Current reportSEC
424B5 · ProspectusJul 25, 2025Offer documentSEC
6-K · Report of a foreign issuerJun 30, 2025Current reportSEC
6-K · Report of a foreign issuerMay 30, 2025Current reportSEC
6-K · Report of a foreign issuerMay 27, 2025Current reportSEC
6-K · Report of a foreign issuerMay 23, 2025Current reportSEC
424B5 · ProspectusApr 11, 2025Offer documentSEC
6-K · Report of a foreign issuerMar 31, 2025Current reportSEC
20-F · Annual reportMar 31, 2025Annual reportSEC
6-K · Report of a foreign issuerJan 21, 2025Current reportSEC
6-K · Report of a foreign issuerJan 17, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 10, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJan 7, 2025Current reportSEC
424B5 · ProspectusJan 7, 2025Offer documentSEC
6-K · Report of a foreign issuerJan 6, 2025Current reportSEC
S-8 · Registration statement for employee plansDec 27, 2024Offer documentSEC
6-K · Report of a foreign issuerNov 25, 2024Current reportSEC
6-K · Report of a foreign issuerNov 21, 2024Current reportSEC
424B5 · ProspectusNov 21, 2024Offer documentSEC
6-K · Report of a foreign issuerNov 12, 2024Current reportSEC
6-K · Report of a foreign issuerNov 5, 2024Current reportSEC
6-K · Report of a foreign issuerOct 16, 2024Current reportSEC
6-K · Report of a foreign issuerOct 1, 2024Current reportSEC
6-K · Report of a foreign issuerAug 19, 2024Current reportSEC
6-K · Report of a foreign issuerAug 15, 2024Current reportSEC
6-K · Report of a foreign issuerJun 18, 2024Current reportSEC
6-K · Report of a foreign issuerMay 30, 2024Current reportSEC
6-K · Report of a foreign issuerMay 28, 2024Current reportSEC
6-K · Report of a foreign issuerMay 24, 2024Current reportSEC
6-K · Report of a foreign issuerMay 17, 2024Current reportSEC
6-K · Report of a foreign issuerMay 6, 2024Current reportSEC
6-K · Report of a foreign issuerApr 17, 2024Current reportSEC
6-K · Report of a foreign issuerApr 10, 2024Current reportSEC
6-K · Report of a foreign issuerApr 1, 2024Current reportSEC
424B5 · ProspectusApr 1, 2024Offer documentSEC
20-F/A · Annual report, amendedMar 26, 2024Annual reportSEC
20-F · Annual reportMar 26, 2024Annual reportSEC
6-K · Report of a foreign issuerMar 26, 2024Current reportSEC
6-K · Report of a foreign issuerMar 4, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 28, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 16, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveJan 8, 2024Other filingsSEC
S-8 · Registration statement for employee plansDec 29, 2023Offer documentSEC
F-3 · Registration statementDec 29, 2023Offer documentSEC
6-K · Report of a foreign issuerDec 21, 2023Current reportSEC
6-K · Report of a foreign issuerDec 12, 2023Current reportSEC
6-K · Report of a foreign issuerNov 20, 2023Current reportSEC
SC 13D · Big-stake noticeOct 26, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerOct 12, 2023Current reportSEC
6-K · Report of a foreign issuerSep 28, 2023Current reportSEC
6-K · Report of a foreign issuerSep 11, 2023Current reportSEC
6-K · Report of a foreign issuerAug 30, 2023Current reportSEC
6-K · Report of a foreign issuerAug 30, 2023Current reportSEC
6-K · Report of a foreign issuerAug 8, 2023Current reportSEC
6-K · Report of a foreign issuerJul 17, 2023Current reportSEC
6-K · Report of a foreign issuerJun 23, 2023Current reportSEC
6-K · Report of a foreign issuerMay 24, 2023Current reportSEC
6-K · Report of a foreign issuerApr 25, 2023Current reportSEC
6-K · Report of a foreign issuerApr 17, 2023Current reportSEC
20-F · Annual reportMar 22, 2023Annual reportSEC
6-K · Report of a foreign issuerMar 22, 2023Current reportSEC
6-K · Report of a foreign issuerMar 6, 2023Current reportSEC
S-8 · Registration statement for employee plansJan 20, 2023Offer documentSEC
6-K · Report of a foreign issuerJan 4, 2023Current reportSEC
6-K · Report of a foreign issuerDec 20, 2022Current reportSEC
6-K · Report of a foreign issuerNov 15, 2022Current reportSEC
6-K · Report of a foreign issuerNov 10, 2022Current reportSEC
6-K · Report of a foreign issuerNov 4, 2022Current reportSEC
6-K · Report of a foreign issuerNov 3, 2022Current reportSEC
6-K · Report of a foreign issuerSep 27, 2022Current reportSEC
6-K · Report of a foreign issuerSep 21, 2022Current reportSEC
424B5 · ProspectusSep 20, 2022Offer documentSEC
6-K · Report of a foreign issuerSep 19, 2022Current reportSEC
6-K · Report of a foreign issuerSep 15, 2022Current reportSEC
6-K · Report of a foreign issuerSep 12, 2022Current reportSEC
20-F/A · Annual report, amendedSep 9, 2022Annual reportSEC
6-K · Report of a foreign issuerAug 16, 2022Current reportSEC
6-K · Report of a foreign issuerJul 5, 2022Current reportSEC
6-K · Report of a foreign issuerJun 28, 2022Current reportSEC
6-K · Report of a foreign issuerJun 16, 2022Current reportSEC
6-K · Report of a foreign issuerMay 27, 2022Current reportSEC
6-K · Report of a foreign issuerMay 11, 2022Current reportSEC
20-F · Annual reportMar 16, 2022Annual reportSEC
6-K · Report of a foreign issuerMar 16, 2022Current reportSEC
6-K · Report of a foreign issuerMar 3, 2022Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 11, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerJan 24, 2022Current reportSEC
6-K · Report of a foreign issuerJan 18, 2022Current reportSEC
6-K · Report of a foreign issuerDec 17, 2021Current reportSEC
6-K · Report of a foreign issuerDec 15, 2021Current reportSEC
6-K · Report of a foreign issuerDec 3, 2021Current reportSEC
6-K · Report of a foreign issuerNov 18, 2021Current reportSEC
6-K · Report of a foreign issuerNov 4, 2021Current reportSEC
6-K · Report of a foreign issuerOct 27, 2021Current reportSEC
6-K · Report of a foreign issuerOct 13, 2021Current reportSEC
CT ORDERSep 21, 2021Other filingsSEC
6-K · Report of a foreign issuerSep 3, 2021Current reportSEC
424B5 · ProspectusSep 3, 2021Offer documentSEC
6-K · Report of a foreign issuerAug 18, 2021Current reportSEC
6-K · Report of a foreign issuerMay 26, 2021Current reportSEC
6-K · Report of a foreign issuerMay 4, 2021Current reportSEC
6-K · Report of a foreign issuerApr 15, 2021Current reportSEC
6-K · Report of a foreign issuerApr 5, 2021Current reportSEC
6-K · Report of a foreign issuerFeb 26, 2021Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 25, 2021Other filingsSEC
POS AM · Amendment to an effective registrationFeb 23, 2021Offer documentSEC
6-K · Report of a foreign issuerFeb 23, 2021Current reportSEC
20-F · Annual reportFeb 23, 2021Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 16, 2021Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2021Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2021Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 29, 2021Big-stake noticeSEC
6-K · Report of a foreign issuerJan 22, 2021Current reportSEC
6-K · Report of a foreign issuerJan 21, 2021Current reportSEC
424B5 · ProspectusJan 21, 2021Offer documentSEC
FWP · Free writing prospectusJan 19, 2021Offer documentSEC
FWP · Free writing prospectusJan 19, 2021Offer documentSEC
424B5 · ProspectusJan 19, 2021Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 12, 2021Other filingsSEC
CORRESP · Letter to the SECJan 11, 2021Other filingsSEC
SC 13G/A · Big-stake notice, amendedJan 6, 2021Big-stake noticeSEC
UPLOAD · Letter from the SECJan 6, 2021Other filingsSEC
F-3 · Registration statementDec 31, 2020Offer documentSEC
424B5 · ProspectusDec 31, 2020Offer documentSEC
6-K · Report of a foreign issuerDec 16, 2020Current reportSEC
6-K · Report of a foreign issuerDec 16, 2020Current reportSEC
6-K · Report of a foreign issuerNov 23, 2020Current reportSEC
6-K · Report of a foreign issuerNov 18, 2020Current reportSEC
424B5 · ProspectusNov 13, 2020Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 3, 2020Big-stake noticeSEC
6-K · Report of a foreign issuerOct 30, 2020Current reportSEC
6-K · Report of a foreign issuerOct 29, 2020Current reportSEC
6-K · Report of a foreign issuerSep 25, 2020Current reportSEC
424B5 · ProspectusSep 25, 2020Offer documentSEC
6-K · Report of a foreign issuerSep 24, 2020Current reportSEC
6-K · Report of a foreign issuerAug 19, 2020Current reportSEC
6-K · Report of a foreign issuerAug 19, 2020Current reportSEC
EFFECT · Notice that a registration is effectiveAug 13, 2020Other filingsSEC
POS AM · Amendment to an effective registrationAug 7, 2020Offer documentSEC
6-K · Report of a foreign issuerAug 6, 2020Current reportSEC
EFFECT · Notice that a registration is effectiveJul 6, 2020Other filingsSEC
424B3 · ProspectusJul 2, 2020Offer documentSEC
UPLOAD · Letter from the SECJul 1, 2020Other filingsSEC
CORRESP · Letter to the SECJul 1, 2020Other filingsSEC
F-1 · Registration statementJun 26, 2020Offer documentSEC
DJun 10, 2020Other filingsSEC
DJun 10, 2020Other filingsSEC
SC 13G · Big-stake noticeJun 5, 2020Big-stake noticeSEC
SC 13G · Big-stake noticeJun 4, 2020Big-stake noticeSEC
SC 13G · Big-stake noticeJun 4, 2020Big-stake noticeSEC
424B5 · ProspectusJun 3, 2020Offer documentSEC
6-K · Report of a foreign issuerJun 3, 2020Current reportSEC
SC 13G/A · Big-stake notice, amendedJun 1, 2020Big-stake noticeSEC
6-K · Report of a foreign issuerJun 1, 2020Current reportSEC
424B5 · ProspectusMay 28, 2020Offer documentSEC
6-K · Report of a foreign issuerMay 28, 2020Current reportSEC
6-K · Report of a foreign issuerMay 27, 2020Current reportSEC
SC 13G · Big-stake noticeMay 26, 2020Big-stake noticeSEC
6-K · Report of a foreign issuerMay 26, 2020Current reportSEC
6-K · Report of a foreign issuerMay 26, 2020Current reportSEC

This page holds 200 of 620 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from BioLineRX Ltd.’s releases

Common shares
2,986,929,790
Fully diluted
2,986,929,790

Fully diluted

LineShares
Common shares2,986,929,790

Share count over time

CountShares
Nov 22, 20262,986,929,790

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Armistice Capital, LLC473KUS$1.11MSep 30, 2026
Citadel30,087US$70,704Sep 30, 2026
Susquehanna20,551US$48,295Sep 30, 2026
Stifel Financial Corp20,041US$47,096Sep 30, 2026
Renaissance Technologies18,900US$44,415Sep 30, 2026
Rhumbline Advisers2,478US$5,821Sep 30, 2026
Wells Fargo1,750US$4,113Sep 30, 2026
Nemes Rush Group LLC250US$588Sep 30, 2026
Tower Research Capital LLC (TRC)181US$425Sep 30, 2026
UBS157US$369Sep 30, 2026
All 17 holders
HolderSharesValueAs of
NewEdge Advisors, LLC82US$193Sep 30, 2026
Osaic Holdings, Inc.51US$119Sep 30, 2026
BFC Planning, Inc.28US$66Sep 30, 2026
SBI Securities Co., Ltd.10US$24Sep 30, 2026
Caitong International Asset Management Co., Ltd2US$5Sep 30, 2026
Danske Bank A/S2US$5Sep 30, 2026
Banque Cantonale Vaudoise1Sep 30, 2026

Big stakes

StakeStakeSharesDateFiling
Armistice Capital, LLC9.99%514KSep 30, 2026Schedule 13G
Highbridge Capital Management LLC7.20%173MJun 30, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Barbara-Jean Anne Bormann-Kennedy
Other companies: Xeris Biopharma Holdings, Inc. (Director · Since at least Oct 5, 2021); BetterLife Pharma Inc. (President, Director · Feb 5, 2015 – Feb 5, 2015 · Past)
Director · Since at least Mar 18, 2026
Aharon Schwartz
Other companies: Protalix BioTherapeutics, Inc. (de) (Director · Since at least Nov 10, 2014)
Director · Since at least Mar 18, 2026
BJ Bormann
Other companies: Xeris Biopharma Holdings, Inc. (Independent, Non-executive Board Member · Since at least Nov 5, 2026)
BOARD MEMBER · Since at least Nov 6, 2026
Philip A Serlin
Other companies: XWELL, Inc. (Director · Feb 15, 2012 – Mar 13, 2012 · Past)
Chief Executive Officer · Since at least Mar 18, 2026
Raphael Hofstein
Other companies: Scopus BioPharma, Inc. (Director · Dec 16, 2020 – Dec 16, 2020 · Past)
Director · Since at least Mar 18, 2026
Avraham MolchoBOARD MEMBER · Since at least Mar 18, 2026
Bela NeimanVICE PRESIDENT, ANALYTICAL CHEMISTRY · Since at least Nov 6, 2026
Efrat HalbfingerVICE PRESIDENT, CHEMISTRY AND FORMULATION · Since at least Nov 6, 2026
Ella SoraniCHIEF DEVELOPMENT OFFICER · Since at least Nov 6, 2026
Gal CohenBOARD MEMBER · Since at least Mar 18, 2026
All 18 people
PersonSeat
Irit Gliko-KabirVICE PRESIDENT, CLINICAL OPERATIONS · Since at least Nov 6, 2026
Jael BirenbergVICE PRESIDENT, REGULATORY AFFAIRS, QUALITY ASSURANCE & PHARMACOVIGILANCE · Since at least Nov 6, 2026
Mali ZeeviCHIEF FINANCIAL OFFICER · Since at least Mar 18, 2026
Philip A. SerlinCHIEF EXECUTIVE OFFICER · Since at least Sep 10, 2026
Rafael HofsteinBOARD MEMBER · Since at least Nov 6, 2026
Rami DarBOARD MEMBER · Since at least Mar 18, 2026
Sandra PanemBOARD MEMBER · Since at least Mar 18, 2026
Shaoyu YanBOARD MEMBER · Since at least Mar 18, 2026

Open People

Log in to ask 6ix AI your own questions about BioLineRX Ltd.